

# James P Allison

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1907143/james-p-allison-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

276  
papers

64,980  
citations

116  
h-index

254  
g-index

283  
ext. papers

75,616  
ext. citations

16  
avg, IF

8.03  
L-index

#	Paper	IF	Citations
276	Restoring function in exhausted CD8 T cells during chronic viral infection. <i>Nature</i> , <b>2006</b> , 439, 682-7	50.4	2903
275	The future of immune checkpoint therapy. <i>Science</i> , <b>2015</b> , 348, 56-61	33.3	2733
274	Enhancement of antitumor immunity by CTLA-4 blockade. <i>Science</i> , <b>1996</b> , 271, 1734-6	33.3	2546
273	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , <b>2018</b> , 359, 97-103	33.3	1895
272	CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. <i>Journal of Experimental Medicine</i> , <b>1995</b> , 182, 459-65	16.6	1595
271	Immunologic correlates of the abscopal effect in a patient with melanoma. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 925-31	59.2	1503
270	Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. <i>Cell</i> , <b>2015</b> , 161, 205-14	56.2	1388
269	CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. <i>Nature</i> , <b>1992</b> , 356, 607-9	50.4	1346
268	Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. <i>Cancer Cell</i> , <b>2014</b> , 25, 719-34	24.3	1332
267	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , <b>2014</b> , 515, 577-81	50.4	1331
266	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 8372-7	11.5	1325
265	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1069-1086	34.4	1297
264	PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 4275-80	11.5	1276
263	The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5323-37	12.9	960
262	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 1695-710	16.6	948
261	Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. <i>Journal of Experimental Medicine</i> , <b>2001</b> , 194, 823-32	16.6	885
260	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. <i>Nature</i> , <b>2012</b> , 482, 400-4	50.4	849

259	Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 190, 355-65	16.6	840
258	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 4712-7	11.5	829
257	CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. <i>Annual Review of Immunology</i> , <b>2001</b> , 19, 565-94	34.7	759
256	CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. <i>Journal of Experimental Medicine</i> , <b>1996</b> , 183, 2533-40	16.6	756
255	ICOS co-stimulatory receptor is essential for T-cell activation and function. <i>Nature</i> , <b>2001</b> , 409, 97-101	50.4	742
254	CTLA-4: new insights into its biological function and use in tumor immunotherapy. <i>Nature Immunology</i> , <b>2002</b> , 3, 611-8	19.1	735
253	Loss of IFN- $\gamma$ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. <i>Cell</i> , <b>2016</b> , 167, 397-404.e9	56.2	688
252	Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. <i>Journal of Experimental Medicine</i> , <b>2009</b> , 206, 1717-25	16.6	677
251	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , <b>2017</b> , 170, 1120-1133.e17	56.2	659
250	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. <i>Nature Immunology</i> , <b>2003</b> , 4, 670-9	19.1	644
249	Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 728-34	12.9	622
248	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , <b>2016</b> , 6, 827-37	24.4	561
247	Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 637-50	16.6	559
246	Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. <i>Nature Medicine</i> , <b>2015</b> , 21, 998-1009	50.5	546
245	The emerging role of CTLA-4 as an immune attenuator. <i>Immunity</i> , <b>1997</b> , 7, 445-50	32.3	542
244	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 205	8.5	538
243	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3005-10	11.5	533
242	CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 1935-45	15.9	531

241	Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. <i>Cell</i> , <b>1988</b> , 55, 837-47	56.2	495
240	Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 226ra32	17.5	484
239	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. <i>Cancer Discovery</i> , <b>2015</b> , 5, 860-77	24.4	476
238	Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 805-12	31.3	460
237	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 1389-402	16.6	452
236	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 5336-41	11.5	452
235	Checkpoint blockade in cancer immunotherapy. <i>Advances in Immunology</i> , <b>2006</b> , 90, 297-339	5.6	414
234	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	409
233	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , <b>2016</b> , 7, 12632	17.4	408
232	Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. <i>Immunity</i> , <b>2002</b> , 16, 23-35	32.3	406
231	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. <i>Nature Medicine</i> , <b>2011</b> , 17, 1094-100	50.5	402
230	Co-stimulation in T cell responses. <i>Current Opinion in Immunology</i> , <b>1997</b> , 9, 396-404	7.8	372
229	Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. <i>Current Opinion in Immunology</i> , <b>2006</b> , 18, 206-13	7.8	367
228	Immune modulation in cancer with antibodies. <i>Annual Review of Medicine</i> , <b>2014</b> , 65, 185-202	17.4	366
227	Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. <i>Cancer</i> , <b>2010</b> , 116, 1767-75	6.4	364
226	Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2861-71	12.9	347
225	A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1810-5	12.9	338
224	CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1998</b> , 95, 10067-71	11.5	334

223	B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. <i>Immunity</i> , <b>2004</b> , 21, 401-13	32.3	331
222	Costimulatory regulation of T cell function. <i>Current Opinion in Cell Biology</i> , <b>1999</b> , 11, 203-10	9	330
221	Epitope landscape in breast and colorectal cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 889-92	10.1	328
220	Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. <i>Immunity</i> , <b>1997</b> , 7, 885-95	32.3	324
219	Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 8099-103	11.5	321
218	B7x: a widely expressed B7 family member that inhibits T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 10388-92	11.5	317
217	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. <i>Nature Medicine</i> , <b>2017</b> , 23, 551-555	50.5	316
216	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , <b>2018</b> , 24, 1804-1808	50.5	297
215	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 20410-5	11.5	291
214	B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 19458-63	11.5	283
213	The B7 family and cancer therapy: costimulation and coinhibition. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5271-9	11.5	277
212	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. <i>Cell Reports</i> , <b>2015</b> , 13, 412-24	10.6	275
211	Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. <i>Journal of Experimental Medicine</i> , <b>2001</b> , 194, 481-9	16.6	274
210	CD28-B7 interactions in T-cell activation. <i>Current Opinion in Immunology</i> , <b>1994</b> , 6, 414-9	7.8	271
209	Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 16723-8	11.5	270
208	Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. <i>Nature</i> , <b>1990</b> , 344, 68-70	50.4	267
207	Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 15095	17.4	255
206	Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 187, 427-32	16.6	250

205	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, 147-164	7.1	248
204	CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. <i>Journal of Experimental Medicine</i> , <b>1993</b> , 177, 1791-6	16.6	243
203	Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2158-67	12.9	235
202	Aire-dependent thymic development of tumor-associated regulatory T cells. <i>Science</i> , <b>2013</b> , 339, 1219-24	33.3	230
201	Expression of Helios in peripherally induced Foxp3+ regulatory T cells. <i>Journal of Immunology</i> , <b>2012</b> , 188, 976-80	5.3	229
200	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. <i>Cancer Discovery</i> , <b>2019</b> , 9, 370-385	34.4	228
199	Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 831-8	12.5	226
198	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. <i>Annals of the New York Academy of Sciences</i> , <b>2013</b> , 1291, 1-13	6.5	215
197	Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. <i>Journal of Immunology</i> , <b>2007</b> , 179, 3926-36	5.3	214
196	Structure, function, and serology of the T-cell antigen receptor complex. <i>Annual Review of Immunology</i> , <b>1987</b> , 5, 503-40	34.7	212
195	TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 1701-11	16.6	207
194	Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. <i>Cancer Research</i> , <b>2012</b> , 72, 430-9	10.1	205
193	The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. <i>Cell</i> , <b>1983</b> , 34, 739-46	56.2	204
192	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. <i>Blood</i> , <b>2008</b> , 112, 1175-83	2.2	196
191	Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 15074-9	11.5	195
190	Augmentation of T cell levels and responses induced by androgen deprivation. <i>Journal of Immunology</i> , <b>2004</b> , 173, 6098-108	5.3	188
189	Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. <i>Journal of Experimental Medicine</i> , <b>2014</b> , 211, 715-25	16.6	186
188	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. <i>Immunological Reviews</i> , <b>2011</b> , 241, 104-18	11.3	185

187	Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. <i>Seminars in Oncology</i> , <b>2010</b> , 37, 473-84	5.5	184
186	Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. <i>Immunological Reviews</i> , <b>2008</b> , 224, 141-65	11.3	182
185	Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. <i>PLoS ONE</i> , <b>2011</b> , 6, e19499	3.7	168
184	Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 9273-8	11.5	167
183	Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. <i>Journal of Experimental Medicine</i> , <b>2008</b> , 205, 2125-38	16.6	167
182	Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. <i>Modern Pathology</i> , <b>2010</b> , 23, 1104-12	9.8	162
181	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1233-1238	12.9	161
180	Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). <i>Current Opinion in Immunology</i> , <b>2010</b> , 22, 326-32	7.8	158
179	The Yin and Yang of T cell costimulation. <i>Science</i> , <b>1995</b> , 270, 932-3	33.3	157
178	The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. <i>Journal of Experimental Medicine</i> , <b>1987</b> , 165, 1076-94	16.6	156
177	Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 229-34	12.5	149
176	T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. <i>Immunity</i> , <b>2007</b> , 26, 311-21	32.3	148
175	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. <i>Cancer Research</i> , <b>2017</b> , 77, 839-850	10.1	145
174	Dissecting the mechanisms of immune checkpoint therapy. <i>Nature Reviews Immunology</i> , <b>2020</b> , 20, 75-76	36.5	141
173	Manipulation of costimulatory signals to enhance antitumor T-cell responses. <i>Current Opinion in Immunology</i> , <b>1995</b> , 7, 682-6	7.8	140
172	In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 11476-81	11.5	139
171	Strength of TCR-peptide/MHC interactions and in vivo T cell responses. <i>Journal of Immunology</i> , <b>2011</b> , 186, 5039-45	5.3	137
170	Thymocyte development is normal in CTLA-4-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 9296-301	11.5	131

169	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 11919-11924	11.5	127
168	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , <b>2015</b> , 25, 208-24	24.7	126
167	Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. <i>Immunological Reviews</i> , <b>2009</b> , 229, 67-87	11.3	126
166	Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 266-71	11.5	122
165	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 22699-22709	11.5	119
164	Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. <i>International Immunology</i> , <b>1996</b> , 8, 519-23	4.9	119
163	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 39-46	50.5	119
162	Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 743-55	16.6	111
161	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. <i>Clinical and Experimental Immunology</i> , <b>2009</b> , 157, 9-19	6.2	111
160	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5729-5737	12.9	109
159	B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. <i>Journal of Immunology</i> , <b>2004</b> , 172, 34-9	5.3	109
158	Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 3813-3818	15.9	109
157	Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2781-91	12.9	108
156	Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 8603-8	11.5	107
155	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1088-1097	24.4	105
154	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 504-514	50.5	105
153	CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. <i>Vaccine</i> , <b>2004</b> , 22, 1700-8	4.1	104
152	Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. <i>Cancer Research</i> , <b>2009</b> , 69, 7747-55	10.1	101



151	Murine Ia and human DR antigens: homology of amino-terminal sequences. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1978</b> , 75, 3953-6	11.5	100
150	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 835-844	12.5	95
149	T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF- $\beta$ cytokine. <i>Immunity</i> , <b>2011</b> , 35, 123-34	32.3	91
148	CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. <i>Journal of Immunology</i> , <b>2006</b> , 177, 1052-61	5.3	91
147	Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 12204-9	11.5	90
146	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	88
145	Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , <b>1997</b> , 73, 57-62	3.5	86
144	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 189-200	12.5	84
143	Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. <i>Journal of Immunology</i> , <b>2005</b> , 174, 1922-31	5.3	84
142	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , <b>2017</b> , 2,	6.2	82
141	Cutting edge: CTLA-4 on effector T cells inhibits in trans. <i>Journal of Immunology</i> , <b>2012</b> , 189, 1123-7	5.3	82
140	Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. <i>Science</i> , <b>2008</b> , 319, 215-20	33.3	82
139	Activation and differentiation requirements of primary T cells in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1993</b> , 90, 8987-91	11.5	82
138	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. <i>Nature Communications</i> , <b>2017</b> , 8, 14340	17.4	80
137	Identification of antigen receptor-associated structures on murine T cells. <i>Nature</i> , <b>1985</b> , 314, 107-9	50.4	79
136	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 6187-92	11.5	77
135	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , <b>2021</b> , 11, 838-857	24.4	76
134	Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. <i>Cancer Immunology Research</i> , <b>2013</b> , 1, 235-44	12.5	75

133	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 22246-22251	11.5	74
132	CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 1137-46	7.4	74
131	Attenuated T cell responses to a high-potency ligand in vivo. <i>PLoS Biology</i> , <b>2010</b> , 8, e1000481	9.7	73
130	Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 17765-70	11.5	73
129	Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 188, 651-9	16.6	73
128	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , <b>2017</b> , 8, 451	17.4	72
127	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 1845-1851	50.5	72
126	CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. <i>Blood</i> , <b>2004</b> , 103, 4594-601	2.2	68
125	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 603	17.4	67
124	Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. <i>Cancer Research</i> , <b>2008</b> , 68, 6054-8	10.1	65
123	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , <b>2015</b> , 7, 967-980	3.8	64
122	A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. <i>Cell</i> , <b>1987</b> , 49, 143-51	56.2	64
121	Interdependent IL-7 and IFN- $\gamma$ signalling in T-cell controls tumour eradication by combined CTLA-4+PD-1 therapy. <i>Nature Communications</i> , <b>2016</b> , 7, 12335	17.4	63
120	Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 881-6	11.5	63
119	Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 12711-6	11.5	61
118	Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E5290-9	11.5	59
117	The T-cell antigen receptor gamma gene: rearrangement and cell lineages. <i>Trends in Immunology</i> , <b>1987</b> , 8, 293-6		59
116	Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 3013-7	11.5	58

115	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , <b>2021</b> , 27, 1432-1441	50.5	57
114	Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 970-80	12.5	55
113	Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. <i>Cancer Cell</i> , <b>2007</b> , 12, 192-9	24.3	55
112	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	54
111	T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. <i>International Immunology</i> , <b>1993</b> , 5, 145-53	4.9	54
110	Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 1113-4	27.4	53
109	Insolubilization of L-asparaginase by covalent attachment to nylon tubing. <i>Biochemical and Biophysical Research Communications</i> , <b>1972</b> , 47, 66-73	3.4	53
108	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.. <i>Science</i> , <b>2021</b> , 374, 1632-1640	33.3	52
107	Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6112-25	12.9	50
106	The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. <i>Immunity</i> , <b>1995</b> , 3, 439-47	32.3	49
105	Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. <i>Experimental Cell Research</i> , <b>1985</b> , 158, 509-18	4.2	49
104	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , <b>2021</b> , 11, 614-625	24.4	49
103	Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 2587-92	11.5	48
102	The role of B7 costimulation in CD4/CD8 T cell homeostasis. <i>Journal of Immunology</i> , <b>2000</b> , 164, 3543-53	5.3	48
101	Gamma delta T-cell development. <i>Current Opinion in Immunology</i> , <b>1993</b> , 5, 241-6	7.8	48
100	Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 1683-94	16.6	47
99	Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 1263-70	7.4	47
98	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. <i>Blood</i> , <b>2015</b> , 125, 3335-46	2.2	46

97	Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. <i>Journal of Immunology</i> , <b>2002</b> , 169, 4094-7	5.3	46
96	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 81	22.4	46
95	Itk negatively regulates induction of T cell proliferation by CD28 costimulation. <i>Journal of Experimental Medicine</i> , <b>1997</b> , 186, 221-8	16.6	44
94	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 1903-1909	12.5	44
93	Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. <i>Immunity</i> , <b>2019</b> , 50, 1084-1098.e10	32.3	43
92	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncolimmunology</i> , <b>2016</b> , 5, e1136044	7.2	42
91	SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3509-14	11.5	42
90	Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. <i>Journal of Immunology</i> , <b>2005</b> , 175, 4199-207	5.3	42
89	Intrathymic differentiation of V gamma 3 T cells. <i>Journal of Experimental Medicine</i> , <b>1993</b> , 178, 309-15	16.6	42
88	T cell-mediated elimination of B7.2 transgenic B cells. <i>Immunity</i> , <b>1997</b> , 6, 327-39	32.3	41
87	ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. <i>Cancer Research</i> , <b>2016</b> , 76, 3684-9	10.1	41
86	Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 3106-11	3.1	39
85	Augmented IL-15R $\alpha$ expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. <i>Journal of Immunology</i> , <b>2012</b> , 188, 6156-64	5.3	38
84	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 100-105	12.5	37
83	mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	37
82	Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2006</b> , 24, 442-7	2.8	37
81	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. <i>British Journal of Haematology</i> , <b>2005</b> , 130, 809-24	4.5	37
80	Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. <i>Journal of Immunology</i> , <b>2015</b> , 194, 2089-98	5.3	33

79	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Response. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3469-3470	12.9	32
78	Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 1390-1395	12.5	30
77	Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. <i>Cytotherapy</i> , <b>2009</b> , 11, 912-22	4.8	30
76	HLA antigens in serum. <i>Methods in Enzymology</i> , <b>1984</b> , 108, 614-24	1.7	30
75	TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10453-10462	11.5	29
74	Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF- $\kappa$ B signaling improves the efficacy of immunotherapy in a brain cancer model. <i>Neurotherapeutics</i> , <b>2012</b> , 9, 827-43	6.4	29
73	Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1011-1018	12.9	28
72	CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. <i>Oncotmunology</i> , <b>2012</b> , 1, 544-546	7.2	28
71	Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 849-54	12.5	27
70	Immunotherapeutic strategies for high-risk bladder cancer. <i>Seminars in Oncology</i> , <b>2007</b> , 34, 165-72	5.5	27
69	H-2 antigens on a murine lymphoma are associated with additional proteins. <i>Nature</i> , <b>1978</b> , 271, 165-7	50.4	27
68	B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. <i>Journal of Immunology</i> , <b>2012</b> , 189, 4165-74	5.3	26
67	Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactions in vivo: correlation with arrest of T cell differentiation. <i>European Journal of Immunology</i> , <b>1989</b> , 19, 857-63	6.1	26
66	Vaccination with tumor cells expressing IL-15 and IL-15R $\alpha$ inhibits murine breast and prostate cancer. <i>Gene Therapy</i> , <b>2014</b> , 21, 393-401	4	25
65	The murine T cell antigen receptor and associated structures. <i>Immunological Reviews</i> , <b>1984</b> , 81, 145-60	11.3	25
64	Biosynthesis and processing of murine T-cell antigen receptor. <i>Cell</i> , <b>1984</b> , 38, 659-65	56.2	25
63	Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulinitis and destruction of beta cells. <i>Blood</i> , <b>2007</b> , 110, 954-61	2.2	23
62	The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction. <i>European Journal of Immunology</i> , <b>1996</b> , 26, 3224-9	6.1	23

61	Cell surface expression by adult rat hepatocytes of a non-collagen glycoprotein present in rat liver biomatrix. <i>Experimental Cell Research</i> , <b>1984</b> , 152, 402-14	4.2	22
60	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 279-88	12.5	22
59	Checkpoints. <i>Cell</i> , <b>2015</b> , 162, 1202-5	56.2	21
58	Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 1803-1812	12.5	21
57	Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. <i>Journal of Experimental Medicine</i> , <b>1993</b> , 177, 1061-70	16.6	21
56	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. <i>Blood</i> , <b>2019</b> , 134, 830-830	2.2	21
55	Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 9872-7	11.5	20
54	Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. <i>International Immunology</i> , <b>1991</b> , 3, 385-93	4.9	20
53	The gamma T-cell antigen receptor. <i>Journal of Clinical Immunology</i> , <b>1987</b> , 7, 429-40	5.7	20
52	A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation. <i>Blood</i> , <b>2018</b> , 132, 296-296	2.2	20
51	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , <b>2018</b> , 132, 905-905	2.2	19
50	Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. <i>Arthritis Research</i> , <b>2004</b> , 6, 208-14		18
49	Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. <i>Developmental Biology</i> , <b>1982</b> , 91, 389-96	3.1	18
48	To be or not to be B7. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 2590-3	15.9	16
47	Characterization and Comparison of GITR Expression in Solid Tumors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6501-6510	12.9	14
46	Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse. <i>Journal of Autoimmunity</i> , <b>2000</b> , 14, 123-31	15.5	14
45	Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. <i>International Immunology</i> , <b>1993</b> , 5, 1451-60	4.9	14
44	The substrate specificity of L-asparaginase from <i>Alcaligenes eutrophus</i> . <i>FEBS Letters</i> , <b>1971</b> , 14, 107-108	3.8	14

43	Prostate cancer: advances in immunotherapy. <i>BioDrugs</i> , <b>2003</b> , 17, 131-8	7.9	11
42	Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. <i>Blood</i> , <b>2018</b> , 132, 906-906	2.2	11
41	A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. <i>Genomics</i> , <b>2006</b> , 88, 841-845	4.3	10
40	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3556-3566	12.9	10
39	Frontiers in cancer immunotherapy-a symposium report. <i>Annals of the New York Academy of Sciences</i> , <b>2021</b> , 1489, 30-47	6.5	10
38	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.. <i>Cancer Cell</i> , <b>2022</b> , 40, 509-523.e6	24.3	10
37	Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". <i>Immunobiology</i> , <b>2012</b> , 217, 590-2	3.4	9
36	Inhibitors of B7-CD28 costimulation in urologic malignancies. <i>Immunotherapy</i> , <b>2009</b> , 1, 129-39	3.8	9
35	The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. <i>Blood</i> , <b>2002</b> , 99, 4509-16	2.2	9
34	Diminished expression of the T cell receptor on the expanded lymphocyte population in MRL/Mp-lpr/lpr mice. <i>Autoimmunity</i> , <b>1989</b> , 2, 97-111	3	9
33	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , <b>2020</b> , 11, 1839	17.4	9
32	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	8
31	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4557-4565	12.9	8
30	MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). <i>International Immunology</i> , <b>2004</b> , 16, 895-904	4.9	7
29	Gamma delta antigen receptors of Thy-1+ dendritic epidermal cells: implications for thymic differentiation. <i>Immunologic Research</i> , <b>1988</b> , 7, 292-302	4.3	7
28	Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	7
27	Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. <i>Journal of Immunology</i> , <b>2013</b> , 190, 526-30	5.3	6
26	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 5045	17.4	6

25	Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. <i>Journal of Immunology</i> , <b>2017</b> , 199, 974-981	5.3	5
24	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , <b>2021</b> , 12, 6071	17.4	5
23	Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e35222	3.7	4
22	Nobels: Toll pioneers deserve recognition. <i>Nature</i> , <b>2011</b> , 479, 178	50.4	4
21	Nucleotide and deduced amino acid sequence of a murine cDNA clone encoding one member of the hsp65 multigene family. <i>Nucleic Acids Research</i> , <b>1990</b> , 18, 7153	20.1	4
20	Response to Comment on Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells. <i>Journal of Immunology</i> , <b>2012</b> , 189, 500.2-501	5.3	3
19	Characterization of env gene recombination in x-ray--induced thymomas of C57BL/6 mice. <i>Molecular Carcinogenesis</i> , <b>1989</b> , 2, 126-30	5	3
18	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment <b>2021</b> , 9,		3
17	Lymphocyte activation and effector functions. How signals are integrated in the immune system. <i>Current Opinion in Immunology</i> , <b>1997</b> , 9, 293-5	7.8	2
16	Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma. <i>Immunogenetics</i> , <b>1983</b> , 17, 655-9	3.2	2
15	Immune Co-signaling to Treat Cancer <b>2013</b> , 211-280		1
14	Training procedures and task difficulty in brightness and position discriminations by rats. <i>Psychological Reports</i> , <b>1972</b> , 31, 71-6	1.6	1
13	Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. <i>Blood</i> , <b>2018</b> , 132, 4585-4585	2.2	1
12	Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy		1
11	Checkpoint Blockade + Chemotherapy: the Right Combination for AML?. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 551-554	7	1
10	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. <i>Blood</i> , <b>2020</b> , 136, 43-45	2.2	0
9	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabm6420	17.5	0
8	Cancer Immunotherapy <b>2017</b> , 1-23		



7 Fc Gamma R **2017**, 209-228

6 Retrospective. Lloyd J. Old (1933-2011). *Science*, **2012**, 335, 49

33.3

5 The congenic mutant B6.C-H-2bm-1 (H-2bm-1) serological response to the T-cell receptor on EL4. *Cellular Immunology*, **1986**, 101, 586-92

4.4

4 Structural differences in envelope glycoproteins associated with rat leukaemia virus produced by Novikoff hepatocellular carcinoma and spontaneously transformed Wistar rat embryo cells. *Journal of General Virology*, **1984**, 65 ( Pt 4), 743-60

4.9

3 Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. *Blood*, **2020**, 136, 29-31

2.2

2 Checkpoint Blockade and Combinatorial Immunotherapies **2007**, 363-390

1 Protein Localization in Negative Signaling **2003**, 355-359